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Abstract: The present study longitudinally evaluated growth, bone mineral density, body composi-
tion, and metabolic health outcome in very low birth weight (VLBW) infants whose in-hospital target
nutrient intake was within recent recommendations. From six months to three years, bone mineral
density (dual-energy X-ray absorptiometry, DXA), body composition, and metabolic health outcome
were compared with a reference group of term infants. The aim was to test whether in-hospital
achieved weight gain until 36 weeks of gestation (light or appropriate for term equivalent age; LTEA
or ATEA) predicts later growth, bone mineral density (BMD), abdominal obesity, or metabolic health
outcomes such as insulin resistance, relative to term infants, during the first three years of life. Target
in-hospital energy and protein intake was not achieved. Growth in weight, length and head circum-
ference, mid arm circumference, adiposity, fat free mass (FFM), and bone mineralization in VLBW
infants was less than those in term infants and influenced by nutritional status at discharge. Preterm
infants had poorer motor and cognitive outcomes. Post-discharge body composition patterns indicate
FFM proportional to height but lower fat mass index in LTEA preterm infants than term infants, with
no evidence of increased truncal fat in preterm infants. The hypothesis of early BMD catch-up in
VLBW infants after discharge was not supported by the present data. The clinical significance of
these findings is unclear. The data may suggest a reduced obesity risk but an increased osteoporosis
risk. Since postnatal growth restriction may have permanent negative health effects, LTEA VLBW
infants would especially appear to benefit from targeted preventive interventions. Further follow-up
of the infants is required.
Keywords: body composition; dual-energy X-ray absorptiometry; outcome; preterm infant; very low
birth weight
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1. Introduction
The goal for the nutritional care in preterm infants is to achieve intra-uterine growth
and body composition to obtain a functional outcome similar to term infants [1]. This
concept is supported by the observed associations between postnatal nutritional deficits
and/or growth failure and long-term neurodevelopmental impairment or metabolic syn-
drome surrogate markers such as higher blood pressure, abdominal obesity, and impaired
glucose tolerance [2–5]. Updating of recommendations requires meticulous assessment
of outcome in growth, body composition, bone mineral density, and metabolic health
outcome. International recommendations for parenteral and enteral nutrition are regularly
updated [6,7]. Very low birth weight (VLBW) infants frequently experience suboptimal nu-
trient intake and exhibit growth failure within the neonatal intensive care units (NICU) [2].
In addition, disease severity and postnatal extracellular volume contraction have been
suggested to contribute to postnatal growth failure [8,9]. Suboptimal nutrient intake may
permanently affect later cognitive attainment [2]. On the other hand, more recent data
suggest that with improved nutritional care early postnatal growth failure in preterm
infants is inevitable [8,10,11]. However, at the time of discharge from the hospital or at term
equivalent age (TEA), a considerable percentage of VLBW infants still appear growth re-
tarded (light for TEA (LTEA) defined by a weight standard deviation (SD) score at 36 weeks
of gestation less than -2 SD) [12]. Given the improvement in nutritional care, it is even more
important to understand the relationship between being discharged LTEA and long-term
outcomes in this population [10].
Several aspects of body composition, in particular the amount and distribution of
body fat, are now understood to be important health outcomes in infants and children, and
dual-energy X-ray absorptiometry (DXA) remains the gold standard for body composition
assessment [13]. The body composition at TEA of infants born preterm is reported to
be different from that of infants born at term. Less lean tissue but similar fat mass (FM)
have been found [14]. On the other hand, fat mass index (FMI) has been reported to be
significantly lower in preterm infants at 8–12 years of age [15] in contrast to more total
fat mass in young adults after preterm birth [16]. Therefore, there is a need to determine
whether improved in hospital nutritional management can enhance lean tissue acquisition.
Hence, a need for measuring body composition in the clinical management of these patients
has been proposed [14].
Low birth weight (LBW) is associated with an increased risk of insulin resistance,
truncal accumulation of fat, metabolic syndrome, and cardiovascular disease in adult-
hood [17,18]. Likewise, in preterm infants, weight gain before discharge and during the
first 3 months post-discharge weight gain have been related to later metabolic disease
or obesity [19,20]. On the other hand, in adolescents born preterm, weight gain during
childhood is reported to be strongly associated with adverse metabolic outcome but not
pre-discharge or early post-discharge growth [21]. Notably, the effect of birth weight on
insulin resistance and later cardiovascular disease (CVD) is most apparent in the upper
tercile of normal BMI and in obese subjects. The greatest variation in rates of weight gain is
seen in the first two years of life when infants may show significant “catch-up” or “catch-
down” growth. At the opposite extreme, the effect of high birth weight on later insulin
resistance and cardiovascular disease is less clear [18]. These studies suggest that there may
be an optimal range for healthy growth. Although, preterm birth is strongly associated
with some components of metabolic syndrome and cardiovascular disease in adult life [22],
postnatal programming of body composition and metabolic health outcomes in preterm
infants has been sparsely examined. Several short-term studies suggest percentage of
fat mass (FM%) catch up or recovery of growth and body composition within the first
6 months after discharge [23]. However, the long-term effects of postnatal growth failure
on body composition and metabolic health outcomes have not been studied sufficiently.
Body fat distribution (trunk-abdominal level) has an impact on health as well. Truncal
fat is the major component of body fat associated with metabolic diseases, including insulin
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resistance, type 2 diabetes, hypertension, and dyslipidemia, leading to increased risk of CVD
or metabolic syndrome [24]. Abdominal adiposity can be reliably assessed by DXA [25].
White adipose tissue is an active player in the regulation of energy balance and
metabolic homeostasis. It expresses receptors for most hormonal and neurological signals,
and it synthesizes a wide variety of peptides that have both paracrine and endocrine actions.
For example, circulating resistin, mainly produced by mononuclear cells in the adipose
tissue matrix, is positively associated with interleukin 6 (IL-6) levels [26]. Numerous other
factors and hormones are involved in metabolism and growth and could be modulated
by the early nutritional environment. The insulin-like growth factor (IGF) system, and in
particular IGF-1, has an important role in the regulation, differentiation, and proliferation
of many cell types, acting as a major growth regulator in humans. Ghrelin, an enteric
hormone with potent appetite stimulating effects, also stimulates growth hormone (GH)
release [27]. Adults born preterm were shown to be less insulin sensitive than those born
at term as assessed by hyperglycemic clamps. The leptin/soluble leptin receptor (sOB-R)
system plays a key role in energy homeostasis [5]. The sOB-R is the main leptin binding
protein, and the ratio of serum leptin to sOB-R provides a measure of the free leptin index,
which may be a more accurate determinant of leptin function [28].
Finally, being born preterm or VLBW is associated with significant motor impair-
ment persisting throughout childhood [29]. Growth from birth to discharge seemed to be
associated with long-term motor development [30].
In the present study, target nutrient intake was within the recent European Society
of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommenda-
tions [6,7]. We hypothesized that VLBW infants who were appropriate for TEA (ATEA;
defined by a SD weight score > −2 at 36 weeks) near discharge will have higher growth
rates, lean body mass and fat mass, skeletal mineral deposition, and neurodevelopmen-
tal scores throughout the first three years of life than LTEA preterm infants. Thus, the
objectives of this study were as follows:
(a) To longitudinally evaluate growth, body composition, bone mineral density, and
metabolic health outcomes from six months to three years of life in a prospective co-
hort of VLBW infants starting at 36 weeks postmenstrual age, relative to term infants.
(b) To test in these infants whether growth status near discharge (LTEA vs. ATEA)
predicts later growth retardation, bone mineral density, abdominal obesity, insulin
resistance, or other associated metabolic health outcomes, relative to term infants,
during the first three years of life.
(c) To analyze whether growth status near discharge (LTEA vs. ATEA) still predicts
neurocognitive and motor-developmental outcome at two years of age.
2. Materials and Methods
2.1. Study Design and Population
A prospective, longitudinal, cohort study on growth and body composition in preterm
and term infants from 6 to 36 months corrected age was performed. Infants were recruited
from the Department of Neonatology at La Paz University Hospital. Among all consecu-
tively born infants less than 34 weeks of gestation and less than 1500 g, 94 were considered
eligible. Preterm infants were classified at TEA age as LTEA (n = 55, body weight (BW)
z-score < −2 SD, according to Alexander growth charts [31]) or ATEA (n = 39, BW z-score
≥ −2 SD). A group of healthy, full-term infants (n = 34) was randomly recruited from
the maternity wards as a reference group. Exclusion criteria were congenital diseases,
chromosomal abnormalities, short bowel syndrome, or other digestive disorders in which
absorption of nutrients was impaired. The study was approved by the local research ethics
committee, and written informed parental consent was obtained.
The infants, together with an accompanying parent, were admitted to the Neonatology
outpatient clinic at La Paz University Hospital in Madrid, Spain, between 08:00 and 09:00, at
6, 12, 18, 24, and 36 months of corrected age. To complete all necessary measurements, the
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infants usually stayed for 4–5 h. Overnight fasting blood samples were obtained between
08:30 and 09:30 h.
2.2. Anthropometry and Analytical Measurements
Weight, length, head circumference, upper arm circumference, and skinfold thicknesses
(biceps, triceps, subscapular, suprailiac) were measured in duplicate, averaged, and recorded
in every visit by 1 of 3 trained observers. Weight was measured accurate to the nearest 10 g
(Seca electronic infant scale, Seca 375, Hamburg, Germany). Length was measured accurate
to the nearest 0.1 cm (Seca infant length board, Seca 210, Hamburg, Germany). Skinfolds
were measured using a Holtain caliper (Holtain Ltd., Crosswell, Crymych, Pembs, UK.).
Circumferences were measured to the nearest mm by flexible measuring tapes.
After overnight fasting, blood samples were obtained between 08:00 h and 09:00 h,
centrifuged at 4 ◦C, and the serum was stored at −80 ◦C until assayed. Serum glucose, total
cholesterol, ferritin, and triglycerides were immediately quantified by enzymatic methods
(autoanalyzer). Commercial radioimmunoassay (RIA) kits were used for measurement
of the serum concentrations of adiponectin, acylated and total ghrelin and leptin (Linco,
Inc., St. Louis, MO, USA). Resistin was measured by an enzyme-linked immunosorbent
assay (ELISA) from Merck Millipore (Billerica, MA, USA). Insulin was determined by
RIA (Diagnostic Products Corporation, Los Angeles, CA, USA), IGFBP-1 was measured
by ELISA (Medix Biochemica, Kauniainen, Finland), and IGF-1 and IGFBP-3 by RIA
(Mediagnost, Tübingen, Germany). IL-6 concentrations were determined by ultrasensitive
ELISA kits from R&D Systems (Minneapolis, MN, USA) and sOB-R levels by ELISA (Bio-
Vendor, Brno, Czech Republic). In all cases intra- and inter-assay coefficients of variations
were lower than 10%. HOMA index was calculated as follows: HOMA index = plasma
glucose (mmol/L) * serum insulin level (mU/mL)/22.5.
2.3. Dual-Energy X-ray Absorptiometry
Child DXA scans were performed at 6, 12, 18, 24, and 36 months (Lunar-DPX-MD;
GE Healthcare, Chalfont St. Giles, UK). Scans were analyzed by using infant whole-body
analysis software (GE Healthcare, Chalfont St. Giles, UK). All DXA scans were performed
with the same device and software. Previously reported precision values for DXA are <1%
for lean mass and <2% for fat mass (FM) in adults [15]. During scanning, infants were
laying supine, wearing only a disposable diaper, swaddled in a light cotton blanket, and
without sedation. Scans were deemed invalid in the case of excessive movements, and
the infants were not re-scanned. Whole-body composition (total fat and lean mass) and
regional (truncal) composition, whole-body bone mineral content (BMC), and bone mineral
density (BMD) were measured. FM and fat free mass (FFM) were normalized for body
weight and for height to give FM%, fat free mass percentage (FFM%), FMI, and fat-free
mass index (FFMI), respectively. The percentage of truncal fat (PTF) was calculated using
the following formula: PTF = total truncal fat/total fat × 100.
2.4. Clinical Characteristics
Data on clinical characteristics such as the score for neonatal acute physiology (SNAP),
patent ductus arteriosus (PDA), late onset sepsis (LOS), chronic lung disease, Bell stage ≥2
necrotizing enterocolitis (NEC), periventricular leukomalacia (PVL), and retinopathy of
prematurity (ROP) were extracted from the medical records (data not shown). A PDA was
recorded if hemodynamically significant based on clinical an echocardiographic criteria.
Chronic lung disease was defined as oxygen dependence at 36 weeks postmenstrual age.
LOS was defined as clinical signs of septicemia beyond 72 h of age together with a positive
blood culture. Only NEC ≥ grade 2, as defined by Bell et al. [32], was considered. Volpe
classification system was used for classification of intraventricular hemorrhage [33]. PVL
was graded and defined according to de Vries et al. [34]. ROP was graded according to the
international classification system [35]. Illness severity and mortality risk scores were cal-
culated at 24 h (score for neonatal acute physiology, SNAP) and 28 days (SNAP-II) [36,37].
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2.5. Neurodevelopment Outcome
At 2 years, corrected age neurodevelopmental outcome was assessed by Bayley Scales
of Infant Development (2nd edition). These assessments were performed and scored by a
certified examiner who was masked to neonatal treatments and complications.
2.6. Statistical Analysis
Descriptive data are presented as the mean ± SD. SPSS version 9.0 was used for
analyzing the data. In preterm infants age in months refers to corrected age. Student’s t test
was used to compare groups (level of significance p = 0.05). Mixed model linear analyses,
for growth, body composition, and biochemical indices, were performed. Group effect,
time effect, and interaction between group and time were analyzed using likelihood ratio
tests (LRTs). Individuals were included as random effect into the model to account for
repeated measurements. Wald statistic p values are given in the tables.
General linear logistic regression models were used to test for differences in motor
and mental development between LTEA and ATEA infants after adjusting for sex and
potential confounding factors (SNAP score, SNAP-II score, PDA, ROP, late onset sepsis,
chronic lung disease, NEC, and PVL).
3. Results
3.1. Characteristics of the Study Population
Anthropometric data at birth in all infants and at TEA in preterm infants are given in
Table 1. In term infants at birth weight, length, head circumference, and gestational age
were higher than in preterm infants (p < 0.001). Weight z score at birth was significantly
lower in LTEA infants than in term and ATEA infants. At TEA weight, length, head
circumference, weight z score, and arm circumference were significantly different between
LTEA and ATEA infants.
Table 1. Anthropometric data at birth and 36 weeks postmenstrual age.
Characteristics Patients Group Birth 36 Weeks Postmenstrual Age
Weight (g)
Term (n = 34) 3299 ± 462 †,γ
ATEA (n = 39) 1112 ± 214 2141± 219 *
LTEA (n = 55) 1025 ± 279 1686± 245
Length (cm)
Term 49.2 ± 2.2 †,γ
ATEA 36.0 ± 4.0 43.8 ± 1.4 *
LTEA 35.7 ± 3.4 40.8 ± 2.3
Head circumference (cm)
Term 35.2 ± 1.6 †,γ
ATEA 25.9 ± 2.0 31.8 ± 1.3 *
LTEA 25.2 ± 2.7 30.3 ± 1.2
Weight z score
Term −0.37 ± 0.93 †
ATEA −0.46 ± 0.49 * −1.6 ± 0.3 *
LTEA −1.19 ± 0.66 −2.6 ± 0.5
Gestational age (weeks)
Term 39 ± 1 †,γ
ATEA 28 ± 2 *





Mid arm circumference (cm)
ATEA 8.8 ± 0.5 *
LTEA 8.0 ± 0.7
Data are expressed as mean ± SD unless stated. ATEA, appropriate for term equivalent age; LTEA, light for term
equivalent age; † Term vs. LTEA < 0.05; γ Term vs. ATEA p < 0.05; *ATEA vs. LTEA p < 0.05.
The clinical biochemistries at TEA in LTEA and ATEA infants are given in Table 2.
Fasting insulin and HOMA levels were significantly (p < 0.05) lower in LTEA infants.
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Thyroid function was investigated at the beginning of the study in every patient and found
to be normal.
Table 2. Basal serum values of IGF1, IGFBP1, IGFBP3, glucose, insulin, HOMA-IR, cholesterol,
triglycerides, leptin, leptin receptor, adiponectin, resistin, total ghrelin, acyl ghrelin, IL-6, and cortisol
at 36 weeks in LTEA and ATEA infants.
LTEA (n = 45) ATEA (n = 31)
IGF-1 (ng/mL) 75 ± 43 82 ± 47
IGFBP-1 (ng/mL) 37 ± 32 67 ± 113
IGFBP-3 (µg/mL) 1.45 ± 0.42 1.39 ± 0.37
Glucose (mg/dl) 81 ± 22 84 ± 19
Insulin (mcU/mL) 7 ± 5 * 11 ± 7
HOMA-IR 1.49 ± 1.33 * 2.36 ± 1.78
Cholesterol (mg/dL) 111 ± 37 101 ± 26
Triglycerides (mg/dL) 122 ± 51 95 ± 43
Leptin (ng/mL) 2.61 ± 3.08 3.05 ± 2.62
Leptin receptor (U/mL) 64 ± 27 58 ± 24
Adiponectin (µg/mL) 27 ± 11 29 ± 7
Resistin (ng/mL) 31 ± 15 29 ± 18
Total Ghrelin (pg/mL) 2122 ± 970 2011 ± 890
Acyl Ghrelin (pg/mL) 102 ± 82 98 ± 75
IL6 (pg/mL) 3.92 ± 3.56 5.21 ± 4.13
Cortisol (µg/dL) 11 ± 8 11 ± 10
Data are expressed as mean ± SD. * LTEA versus ATEA p < 0.05; IGF-1, insulin-like growth factor; IGFBP-1,
insulin-like growth factor binding protein 1; IGFBP-3, insulin-like growth factor binding protein 3; IL6, interleukin
6; HOMA-IR, homeostatic model assessment for insulin resistance; LTEA, light for term equivalent age; ATEA,
appropriate for term equivalent age.
3.2. Anthropometric Evolution
Anthropometric data from 6 to 36 months of life are given in Table 3. In VLBW infants
weight at TEA predicts growth and skinfold thicknesses during the first three years of life.
Anthropometric indices were consistently higher in term infants than in preterm infants. In
term infants and ATEA infants, a similar growth pattern for head circumference was seen.
In LTEA infants head circumference was significantly smaller in the first three years of life
than in the other groups. LTEA infants had significantly lower subscapular and bicipital
skinfold thickness than term infants. There was no significant difference with regard to
suprailiac skinfold; however, the three groups differed in tricipital skinfold thickness and
mid-arm circumference over time.
3.3. Body Composition and Bone Mineral Density
The time course of body composition analysis by DXA is presented in Table 4. With
growth, absolute amount of total FFM and FM increased gradually during the first three
years of life (significant time effects, p < 0.001). There were significant group and interaction
group x time effects showing at least that FM and FFM were significantly lower in LTEA
infants than in term infants at all time points. In contrast, there were no significant time
effects but significant group and interaction group x time effects with regard to FM(%) and
FFM(%), showing at least that FM(%) was always lower and FFM(%) always higher in
LTEA infants than in term infants. Most importantly, there were significant time, group,
and interaction group x time effects with regard to FMI, showing that FMI decreased in all
groups with time but was always lowest in LTEA infants. FFMI decreased with time in all
groups (significant time effect), and there was no significant difference between the groups
(no group and no interaction group x time effect).
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Table 3. Anthropometric measurements during the first three years of life.










Term 7686 ± 1010 (34) † 9770 ± 1307 (29) †,γ 11079 ± 1406 (17) †,γ 12553 ± 1405 (31) †,γ 14969 ± 1925 (28) †,γ
<0.01 <0.001 <0.001ATEA 7299 ± 823 (31) * 8768 ± 1026 (28) * 9999 ± 1266 (17) 11553 ± 1336 (28) 13260 ± 1645 (20)
LTEA 6306 ± 979 (51) 8085 ± 1213 (43) 9474 ± 1201 (40) 10572 ± 1493 (46) 12117 ± 1640 (41)
Length
(cm)
Term 68.0 ± 2.7 † 76.1 ± 2.3 †,γ 84 ± 4 †,γ 89 ± 4 †,γ 97 ± 4 †,γ
NS <0.001 <0.001ATEA 66.5 ± 3.1 * 73.7 ± 2.6 80 ± 3 87 ± 4 * 93 ± 4
LTEA 63.5 ± 3.2 72.1 ± 3.1 79 ± 3 84 ± 4 91 ± 4
HC
(cm)
Term 44.2 ± 1.7 † 47.2 ± 1.6 † 48.8 ± 1.6 † 49.6 ± 1.8 † 50.8 ± 1.8 †,γ
NS <0.001 <0.001ATEA 43.7 ± 1.2 * 46.3 ± 1.2 * 47.9 ± 1.3 48.9 ± 1.4 * 49.7 ± 1.1 *
LTEA 42.5 ± 1.8 45.2 ± 1.8 46.7 ± 1.5 47.5 ± 1.7 48.4 ± 1.8
Mid arm circum-ference
(cm)
Term 14.5 ± 1.1(34) † 15.4 ± 1.4 (28) † 15.3 ± 1.4 (17) 16.4 ± 1.2 (30) † 16.9 ± 1.4 (28) †
<0.01 <0.001 <0.001ATEA 14.4 ± 0.9 (29) * 14.7 ± 1.1 (28) 15.4 ± 1.3 (17) 15.8 ± 1.3 (22) 16.3 ± 1.1 (18)
LTEA 13.2 ± 1.3 (50) 14.1 ± 1.2 (43) 14.8 ± 1.2 (39) 15.2 ± 1.0 (40) 15.5 ± 1.1 (38)
Sub-scapular skinfold
(cm)
Term 7.1 ± 1.5(34) 6.8 ± 1.3 (29) 6.3 ± 1.5 (17) 6.3 ± 1.4 (30) 6.2 ± 1.4 (28)
NS <0.001 <0.001ATEA 6.9± 1.4 (31) 6.3 ± 1.3 (27) 6.1 ± 1.3 (17) 5.8 ± 1.3 (22) 5.6 ± 1.4 (17)
LTEA 6.2 ± 1.4 (50) 5.6 ± 1.0 (43) 5.5 ± 1.2 (39) 5.3 ± 1.0 (39) 5.1 ±1.0 (38)
Tricipital skinfold
(cm)
Term 7.9 ± 1.9(34) † 7.8 ± 2.5 (29) † 6.3 ± 1.5 (17) 8.2 ± 1.8 (30) 8.6 ± 1.9 (28) †,γ
<0.01 NS <0.001ATEA 8.2 ± 1.8 (31) * 7.3 ± 1.6 (27) 6.8 ± 1.3 (17) 7.5 ± 1.5 (22) 7.3 ± 1.3 (17)
LTEA 6.8 ± 1.3 (50) 6.7 ± 1.5 (43) 6.9 ± 1.2 (39) 7.5 ± 1.5 (39) 7.3 ±1.5 (38)
Bicipital skinfold
(cm)
Term 6.8 ± 1.7(34) † 5.8 ± 1.6 (29) 5.6 ± 1.6 (16) 5.8 ± 1.5 (30) 5.8 ± 1.3 (28)
NS <0.01 <0.001ATEA 6.3 ± 1.2 (31) 5.8 ± 1.7 (27) 5.4 ± 1.6 (17) 5.4 ± 1.1 (22) 5.3 ± 1.3 (17)
LTEA 5.6 ± 1.2 (50) 5.3 ± 1.4 (43) 5.1 ± 1.1 (39) 5.4 ± 1.1 (39) 5.2 ±1.1 (37)
Suprailiac skinfold
(cm)
Term 7.1 ± 1.8(34) 6.3 ± 1.9 (29) 5.2 ± 1.2(15) 6.4 ± 1.7 (30) 5.8 ± 1.9 (28)
NS NS <0.001ATEA 7.4 ± 1.9 (31) 6.2 ± 1.8 (27) 6.7 ± 2.3 (17) 6.3 ± 1.9 (22) 6.6 ± 2.1 (17)
LTEA 6.7 ± 1.8 (50) 5.9 ± 1.7 (42) 6.0 ± 1.9 (39) 6.0 ± 1.4 (39) 6.1 ±1.9 (38)
Data are express as mean ± SD unless stated. ATEA, appropriate for term equivalent age; LTEA, light for term equivalent age; HC, head circumference; m, months; NS, not significant; † Term vs. LTEA < 0.05.
γ Term vs. ATEA p < 0.05. * ATEA vs. LTEA p < 0.05. 1 Linear mixed model.
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Table 4. Body composition and bone densitometry results (by dual-energy X-ray absorptiometry).










Term 2234 ± 681(22) †,γ 2446 ± 865(25) † 2756 ± 854(15) † 2787 ± 840 (24) † 3407 ± 1036(25) †
<0.05 <0.001 <0.001ATEA 1813 ± 625(26) * 2008 ± 681(25) 2241 ± 809(17) 2591 ± 667(14) 2949 ± 920(13)
LTEA 1282 ± 597(46) 1660 ± 580(43) 1877 ± 589(34) 2045 ± 580(35) 2323 ± 588(34)
FFM
(g)
Term 6059 ± 729 † 7451 ± 939 † 8939 ± 795 9581 ± 839 † 11517 ± 1234 †
<0.05 <0.001 <0.001ATEA 5982 ± 517 * 7117 ± 642 8049 ± 952 9221 ± 876 10891 ± 1349
LTEA 5495 ± 675 6832 ± 844 7880 ± 790 8824 ± 978 9796 ± 1213
FM
(%)
Term 27 ± 5(22) †,γ 24 ± 5(25) † 23 ± 6(15) 22 ± 5(24) † 22 ± 4(25)
<0.01 <0.01 NSATEA 23 ± 6(26) 22 ± 6(25) 21 ± 6(17) 22 ± 4(14) 21 ± 5(13)
LTEA 18 ± 6(46) 19 ± 5(43) 19 ± 4(34) 19 ± 4(35) 19 ± 4(34)
FFM
(%)
Term 74 ± 6 †,γ 76 ± 5 † 77 ± 6 78 ± 5 † 78 ± 4
<0.05 <0.01 NSATEA 77 ± 6(26) 78 ± 6 79 ± 6 78 ± 4 79 ± 5
LTEA 82 ± 6(46) 81 ± 5 81 ± 4 81 ± 4 81 ± 4
FMI
(g/cm2)
Term 0.48 ± 0.13 †,γ 0.42 ± 0.13 † 0.39 ± 0.11 0.35 ± 0.09 0.36 ± 0.09
<0.05 <0.01 <0.001ATEA 0.40 ± 0.13 0.37 ± 0.12 0.35 ± 0.12 0.34 ± 0.09 0.34 ± 0.10
LTEA 0.31 ± 0.14 0.32 ± 0.10 0.30 ± 0.08 0.28 ± 0.07 0.28 ± 0.06
FFMI
(g/cm2)
Term 1.31 ± 0.12 (22) 1.28 ± 0.13 (25) 1.26 ± 0.05 (15) 1.21 ± 0.05 (24) 1.21 ± 0.08 (24)
NS NS <0.001ATEA 1.36 ± 0.08 (25) 1.32 ± 0.08 (25) 1.27 ± 0.07 (16) 1.23 ± 0.06 (14) 1.24 ± 0.09 (13)
LTEA 1.36 ± 0.10 (46) 1,31 ± 0.08 (43) 1.27 ± 0.06 (34) 1.23 ± 0.09 (35) 1.17 ± 0.08 (34)
BMD
(g/cm2)
Term 0.57 ± 0.05(30) †,γ 0.63 ± 0.04(25) 0.69 ± 0.05(15) † 0.71 ± 0.05(24) 0.77 ± 0.05(25)
NS <0.001 <0.001ATEA 0.54 ± 0.05(27) 0.60 ± 0.04(25) 0.67 ± 0.05(17) 0.70 ± 0.03(14) 0.75 ± 0.04(13)
LTEA 0.52 ± 0.05(46) 0.60 ± 0.04(43) 0.65 ± 0.06(33) 0.69 ± 0.04(35) 0.74 ± 0.04(34)
BMC
(g)
Term 167 ± 39 †,γ 244 ± 46 † 339 ± 55 †,γ 401 ± 73 †,γ 547 ± 89 †,γ
<0.001 <0.001 <0.001ATEA 129 ± 31 210 ± 41 293 ± 67 377 ± 53 482 ± 64
LTEA 106 ± 29 196 ± 44 281 ± 55 345 ± 56 421 ± 65
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Term 3.62 ± 0.78 †,γ(30) 4.16 ± 0.66 (25) 4.79 ± 0.54 (15) 5.05 ± 0.59 (24) 5.76 ± 0.68 † (24)
<0.001 <0.001 <0.001ATEA 2.90 ± 0.66 (27) 3.87 ± 0.59 (25) 4.69 ± 0.65 (16) 5.00 ± 0.54 (14) 5.49 ± 0.53 (13)
LTEA 2.61 ± 0.62 (46) 3.73 ± 0.66 (43) 4.50 ± 0.68 (34) 4.79 ± 0.64 (35) 5.04 ± 0.55 (34)
TF
(g)
Term 681 ± 230 (30) †,γ 683 ± 368 (25) † 768 ± 300(15) † 728 ± 288 (24) † 984 ± 370 (25) †
<0.01 <0.001 <0.001ATEA 512 ± 237 (27) 538 ± 251 (25) 604 ± 312 (17) 674 ± 229 (14) 865 ± 378 (13)
LTEA 358 ± 186 (46) 440 ± 199 (43) 480 ± 219(34) 519 ± 209 (35) 680 ± 250(34)
PTF
(%)
Term 28 ± 3 26 ± 6 27 ± 3 26 ± 3 28 ± 4
NS NS <0.001ATEA 27 ± 4 26 ± 6 26 ± 5 26 ± 3 29 ± 4
LTEA 28 ± 5 26 ± 4 25 ± 4 25 ± 4 29 ± 5
Data are expressed as mean ± SD unless stated. ATEA, appropriate for term equivalent age; LTEA, light for term equivalent age; BMC, bone mineral content; BMD, bone mineral density; FFM, fat free mass;
FFMI, free fat mass index; FM, fat mass; FMI, fat mass index; PTF, percentage of trunk fat mass; TF, trunk fat; † Term vs. LTEA < 0.05; γ Term vs. ATEA p < 0.05; * ATEA vs. LTEA p < 0.05; 1 Linear mixed model.
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At 6 months of age ATEA infants, in contrast to term infants, were significantly leaner
(less FM, less FM%, less FMI). From that time on ATEA infants were, as a group, always be-
tween term and LTEA infants; however, the study was underpowered to prove significance.
With regard to TF there were significant time, group, and group x time effects, in-
dicating that TF increased over time throughout the study period (p < 0.001). TF was
always significantly higher in term than in LTEA infants and in addition at 6 months also
significantly higher in term than ATEA infants (p < 0.001). However, after appropriate
adjustment for total fat mass, the group effect and the group x time effect disappeared. PTF
varied over time and was lower at 12, 18, and 24 months than at 6 and 36 months, but there
was virtually no difference between the 3 groups.
Significant time, group, and group x time effects were observed in whole-body BMC.
The BMC was significantly lower in preterm than in term infants at nearly all points of
time (exception at 12 months in ATEA infants). After appropriate adjustment for length
(BMC/length2), an interaction between group and time was still present. BMC/length2
significantly increased over time and was significantly lower in LTEA than in term infants.
BMD also significantly increased over time (p < 0.001) and was at least in LTEA infants
significantly lower than in term infant for the whole study period. With regard to ATEA
infants, BMC, BMD, and BMC/length2 were significantly lower than in term infants at
6 months of age. For the rest of the study time bone mineralization measurements in ATEA
infants were between the two other groups but more similar to LTEA infants.
3.4. Metabolic Outcome
A group effect was shown in serum IGF-1 (Table 6, p < 0.05). LTEA had higher serum
IGF-1 levels than term infants. Serum IGFBP-1 changed over time (p < 0.05). Higher serum
IGFBP-1 values were found at 12 months. Serum IGFBP-3 levels changed over time, with
an increase at 36 months. No differences were found between the three groups in total or
acyled ghrelin.
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Table 5. Comparison of cholesterol and triglycerides, adipokines, interleukin 6, IGF family, glucose tolerance parameters, and cortisol between term, LTEA, and ATEA infants.







Term 94 ± 48 34 94 ± 52 26 59 ± 22 16 67 ± 39 29 78 ± 30 29
NS <0.05 NSATEA 108 ± 55 29 117 ± 101 26 88 ± 70 14 95 ± 57 18 88 ± 46 17
LTEA 103 ± 67 48 114 ± 83 40 91 ± 43 35 88 ± 46 37 87 ± 34 40
IGFBP-1 (ng/mL)
Term 52 ± 36 34 65 ± 30 γ 26 43 ± 24 15 43 ± 14 19
NS NS <0.05ATEA 50 ± 28 29 51 ± 25 23 41 ± 12 6 58 ± 30 4
LTEA 49 ± 29 49 55 ± 31 37 45 ± 17 18 37 ± 6 7
IGFBP-3 (µg/mL)
T 2.41 ± 0.5 34 2.56 ± 0.71 25 2.39 ± 0.82 17 2.35 ± 0.80 28 2.61 ± 0.51 29
NS NS <0.01ATEA 2.29 ± 0.51 29 2.38 ± 0.72 25 2.18 ± 0.91 15 2.37 ± 0.80 18 2.70 ± 0.61 17
LTEA 2.37 ± 0.71 50 2.58 ± 0.54 36 2.43 ± 0.9 37 2.25 ± 0.82 41 2.63 ± 0.69 39
Plasma glucose
(mg/L)
T 77 ± 12 8 75 ± 8 26 73 ± 9 17 76 ± 6 29 80 ± 5 29
NS NS <0.01ATEA 80 ± 6 16 76 ± 5 25 75 ± 7 14 77 ± 7 18 78 ± 13 17
LTEA 77 ± 7 31 74 ± 8 41 76 ± 9 40 79 ± 8 43 79 ± 7 41
Insulin (mcU/mL)
T 2.64 ± 1.28 34 2.51 ± 1.24 28 2.44 ± 1.43 17 2.60 ± 1.07 29 3.85 ± 1.70 29
NS NS <0.001ATEA 2.99 ± 1.69 27 2.56 ± 1.33 26 2.58 ± 1.24 15 3.45 ± 1.86 18 3.70 ± 1.64 17
LTEA 3.00 ± 1.62 46 2.66 ± 1.53 39 2.84 ± 1.44 36 3.79 ± 1.77 39 3.49 ± 2.12 40
HOMA
Term 0.5085 ± 0.195 8 0.469 ± 0.244 25 0.454 ± 0.319 17 0.492 ± 0.220 29 0.775 ± 0.370 29
NS NS <0.001ATEA 0.680 ± 0.421 14 0.497 ± 0.288 24 0.488 ± 0.253 14 0.673 ± 0.395 18 0.768 ± 0.390 16
LTEA 0.604 ± 0.338 26 0.493 ± 0.319 37 0.556 ± 0.329 36 0.746 ± 0.398 39 0.695 ± 0.451 40
Cholesterol (mg/dL)
Term 132 ± 33 26 146 ± 25 28 151 ± 28 17 152 ± 27 29 150 ± 27 28
NS NS <0.001ATEA 138 ± 25 27 144 ± 38 26 159 ± 38 15 159 ± 32 18 158 ± 32 17
LTEA 135 ± 24 46 159 ± 29 41 158 ± 28 40 160 ± 35 42 165 ± 30 38
Triglycerides (mg/dL)
Term 105 ± 33 25 116 ± 51 27 81 ± 37 17 70 ± 16 29 68 ± 22 28
NS NS <0.001ATEA 116 ± 41 27 108 ± 41 26 104 ± 61 15 78 ± 26 18 72 ± 26 17
LTEA 114 ± 45 44 107 ± 47 41 87 ± 32 40 79 ± 29 42 67 ± 19 38
Leptin (ng/mL)
T 5.60 ± 2.74 † 34 4.40 ± 4.38 29 2.87 ± 1.21 17 3.30 ± 1.71 29 3.49 ± 1.52 29
<0.05 NS <0.001ATEA 6.16 ± 3.54 * 30 4.31 ± 3.01 * 27 3.75 ± 1.95 15 3.53 ± 1.84 18 4.32 ± 2.69 17
LTEA 4.21 ± 1.80 50 3.18 ± 1.59 43 3.40 ± 1.41 39 3.60 ± 1.56 42 3.28 ± 1.54 40
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Term 66 ± 21 34 72 ± 30 28 66 ± 17 17 72 ± 19 29 50 ± 13 29
NS NS <0.001ATEA 70 ± 21 30 76 ± 27 25 76 ± 20 14 66 ± 21 18 54 ± 17 17
LTEA 69 ± 23 51 79 ± 20 42 76 ± 23 37 68 ± 19 42 57 ± 13 40
Leptin/sOB-R
Term 0.12 ± 0.18 † 34 0.08 ± 0.06 † 28 0.05 ± 0.02 17 0.05 ± 0.03 29 0.08 ± 0.06 29
NS NS <0.001ATEA 0.11 ± 0.12 31 0.08 ± 0.13 25 0.06 ± 0.04 15 0.07 ± 0.06 19 0.11 ± 0.13 18
LTEA 0.07 ± 0.05 49 0.05 ± 0.04 41 0.06 ± 0.06 36 0.06 ± 0.03 41 0.06 ± 0.04 39
Adiponectin (µg/mL)
Term 27 ± 9 32 23 ± 6 28 28 ± 11 17 25 ± 8 29 21 ± 7 28
<0.05 NS <0.05ATEA 25 ± 9 30 24 ± 9 26 22 ± 6 15 20 ± 5 18 20 ± 5 17
LTEA 26 ± 7 50 24 ± 9 44 22 ± 7 37 24 ± 8 42 25 ± 9 40
Resistin (ng/mL)
T 15 ± 10 34 19 ± 8 25 22 ± 9 15 18 ± 9 27 18 ± 8 23
NS <0.05 <0.05ATEA 17 ± 12 29 17 ± 6 25 17 ± 11 13 19 ± 10 16 19 ± 7 15
LTEA 23 ± 16 50 24 ± 12 41 19 ± 9 39 20 ± 10 40 21 ± 11 35
Total Ghrelin
(pg/mL)
T 3107 ± 1951 34 2977 ± 1120 28 2805 ± 1702 17 2406 ± 778 29 2055 ± 702 29
NS NS <0.001ATEA 3465 ± 1739 30 3414 ± 1342 27 2563 ± 991 15 2166 ± 868 18 1923 ± 658 17
LTEA 3222 ± 1385 50 3234 ± 1215 44 2947 ± 1559 39 2343 ± 1050 42 2354 ± 1226 39
Ghrelin acylate
(pg/mL)
T 95 ± 51 34 85 ± 39 28 62 ± 24 17 62 ± 24 29 43 ± 31 29
NS NS <0.001ATEA 82 ± 47 29 79 ± 52 27 64 ± 49 15 58 ± 27 18 44 ± 29 17
LTEA 102 ± 64 51 66 ± 36 43 57 ± 27 39 53 ± 23 40 47 ± 35 40
IL6 (pg/mL)
T 2.77 ± 3.5 31 3.01 ± 2.96 21 2.25 ± 1.29 7 1.82 ± 1.19 14
NS <0.05 NSATEA 1.08 ± 0.83 21 1.73 ± 1.23 17 0.97 ± 0.45 7 1.48 ± 1.76 6
LTEA 2.45 ± 2.14 40 3.11 ± 2.97 33 1.88 ± 1.74 23 2.85 ± 3.16 11
Cortisol (µg/dL)
T 13 ± 5 28 12 ± 4 29 10 ± 2 17 10 ± 4 29 9 ± 3 28
NS <0.01 <0.01ATEA 11 ± 6 27 11 ± 6 27 14 ± 4 15 11 ± 3 18 8 ± 2 16
LTEA 9 ± 5 49 10 ± 5 42 9 ± 4 39 9 ± 4 41 8 ± 2 33
Data are expressed as mean ± SD unless stated. T, term; ATEA, appropriate for term equivalent age; LTEA, light for term equivalent age; M, months; N, number; † Term vs. LTEA < 0.05; γ Term vs. ATEA
p < 0.05; * ATEA vs. LTEA p < 0.05; 1 Linear mixed model.
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An interaction between group and time was observed in serum leptin levels. ATEA
infants had significantly higher leptin than LTEA infants at 6 and 12 months. There was a
significant effect of time on leptin and sOB-R. sOB-R did not differ between groups. LTEA
infants had significantly lower levels of free leptin index (leptin/sOB-R) than term infants.
Serum adiponectin levels showed an interaction between group and time. Resistin levels
changed with group (p < 0.05) and with time (p < 0.05). LTEA infants had higher serum
resistin compared with ATEA and term infants. Values of resistin increased from 6 to
12 months and remained stable thereafter.
From 6 to 36 months HOMA and fasting insulin changed with time (p < 0.001), but
there was no difference between the groups. An effect of group (p < 0.01) and time (p < 0.01)
was observed for cortisol levels. LTEA infants had lower serum cortisol levels compared
with ATEA and term infants, and at three years there was no difference. Circulating IL-6
levels remained unchanged with time, during the first three years of life. No differences
were found between the groups in cholesterol, triglycerides, and plasma glucose.
Ferritin levels (data not shown) were higher in term than preterm infants and higher
at 6 months compared with later on. There was no significant interaction between group
and/or time.
3.5. Neurodevelopmental Outcome
LTEA infants had lower mean Psychomotor Developmental Index PDI (83.7 ± 16.2 vs.
105.4 ± 15.2, p < 0.001) and lower mean Mental Developmental Index MDI (93.3 ± 26.8
vs.108.3 ± 14.1, p < 0.001) than term infants at two years corrected age. In ATEA infants
mean PDI (90.9 ± 11 vs. 105.4 ± 15.2, p < 0.001) and mean MDI (93.8 ± 14 vs.108.3 ± 14.1,
p < 0.001) were also lower than in term infants at two years corrected age. No significant
differences were found between LTEA and ATEA preterm infants in PDI (p = 0.062) and
MDI (p = 0.93), respectively.
4. Discussion
This study was designed primarily to compare growth, development of body compo-
sition, biochemical metabolic health outcomes, as well as the neurodevelopmental outcome
of healthy term infants with that of VLBW preterm infants with protein and energy intakes
close to recommended target intake, within the first 3 years of life. Special consideration
was given to the preterm infants growth status at TEA (LTEA vs. ATEA).
This contemporary, longitudinal, prospective cohort study showed that weight at
TEA significantly predicted growth, body composition, and biochemical metabolic health
outcome, suggesting a programming effect.
4.1. Growth
The present data suggest that body weight near discharge significantly predicts long-
term growth and body composition development in VLBW infants at least for the first three
years of life. Several other studies previously reported early postnatal growth retardation
in preterm infants. The present study adds that this effect is even more pronounced in
VLBW infants who were LTEA near discharge. The weight SD score decreased during
hospitalization on average by 1.14 in ATEA infants and by 1.41 in LTEA infants from birth
to 36 weeks (Table 1). Our target daily intakes for energy and protein for these VLBW
infants were within the recommended range of recent recommendations [6,7]. However,
within the first three weeks of life an average of 95.5% for energy and 86.4% for protein
of the target intake were achieved only [8]. Therefore, even though energy and protein
intake were close to recommended levels, compared to term infants, fetal growth was not
matched, indicating that for the group of VLBW infants nutrient intake was inadequate.
In both groups of VLBW infants, weight, length, HC, mid arm circumference, and
subscapular skinfold thickness were significantly smaller than in term infants throughout
the first 3 years of life (Table 1), and there was no catch-up. These data suggest a postnatal
in hospital programming effect because the majority (92.3%) of the VLBW infants were
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appropriate for gestational age (AGA) at birth (weigh SD score > −2). We hypothesize
that this effect may be modifiable. Subscapular and bicipital skinfold measurements were
smaller in LTEA infants; whereas there was no significant difference between the groups
with regard to suprailiac and tricipital skinfold measurements. In a previous study we
have shown that in VLBW infants weight SD score at birth and disease severity were major
predictors of weight SD score at TEA [8]. Altogether, these data support two important
hypotheses that need to be tested in future trials. First, extrauterine growth before TEA pro-
grams future growth and body composition development. Second, a more individualized
nutritional approach may be required to prevent adverse programming effects.
4.2. Body Composition
This is the first longitudinal study comparing body composition development between
term and preterm infants during the first 3 years of life. Contrary to our hypothesis [38],
our results suggest that the smaller size of LTEA preterm infants compared those infants
born at term is associated with lower FM but higher FFM when normalized for height.
From 6 months corrected age to three years of life, in addition to FM also FM% and
FMI were lowest in LTEA infants (group effect and interaction group x time effect both
<0.05) (Figure 1). These data show that weight at term corrected age has important long-
term impact on growth, suggesting an intrinsic lesser growth potential in infants born
prematurely, particularly if they are light for age at 36 weeks postmenstrual age.
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We report for the first time that this growth retardation has an effect on growth, body
composition, and metabolic response during the first three years of life. Few previous
studies only have examined and reported fat mass and lean mass during early childhood.
Cooke, Rawlings, et al. studied preterm infants (n = 125) during the first year of life. In
contrast to our infants, FM and FM% were higher than in the reference infants, wheras lean
mas was reduced [39]. We speculate that in our infants improv d in-hospital nutrition,
and especially the protein intake close to recommended target intake, may have prevented
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early fat deposition. Beyond the first year of life, the number of studies comparing body
composition between term and preterm infants is very limited. Darendelier et al. did
not find a significant difference in fat mass index (DXA) between the preterm (about
32 weeks of gestation) and term AGA infants, or between the term and preterm SGA
infants at 4–5 years of age [40]. Fewtrell et al. reported similar findings to those reported
here at 8–12 years of age. The FMI and percent body fat were significantly lower in the
preterm infants in contrast to FFMI [15]. Finally, Willemsen et al. found in short SGA
infants at about 6.8 years significantly lower % body fat SD in preterm than in term born
infants. Adjusting for gender did not change the results [41]. Hernandez et al. compared
body composition between AGA and SGA VLBW preterm infants by DXA at 2 years. At
24 months, SGA VLBW infants were lighter and had less fat mass and lean mass than AGA
VLBW infants [42]. Our data do not support the hypothesis that adipose tissue distribution
is altered in preterm infant with significantly increased intraabdominal adiposity. There
was virtually no difference with regard to truncal fat regardless of their different birth
weight and birth weight z-score after appropriate adjustment for total fat mass (Table 4).
4.3. Bone Mineral Density
In term infants BMC measurements at 6 and 12 months were virtually identical to
published reference values [43]. Our data reconfirm studies that previously described in
preterm infants a lower whole-body BMC at TEA than in infants born at full term [44,45].
At 6 months of age, in a previous study, no difference in BMC between preterm and
full-term infants has been found [44], and a catch-up of BMD in preterm infants has been
hypothesized [46]. In contrast, our meticulously performed longitudinal study showed
a lower BMC in both groups of VLBW preterm infants throughout the first 3 years of
life (Figure 2). Even after normalization for body surface area or length, there was still a
significant difference between the three groups within the first 3 years of life.
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For child age conflicting data have been published. One study reports a clear trend
towards a reduced BMD in preterm infants, but no significant difference was found [47],
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whereas others report significantly reduced bone mineral density in former preterm infants
when compared to term infants [48,49]. Previous reviews on bone health in adults did
not indicate a significant effect of birth weight on adult BMC [50]. However, several more
recent studies in adults born preterm with VLBW or SGA found lower adult bone mass,
lower peak bone mass, and higher frequency of osteopenia/osteoporosis, implying an
increased future fracture risk [51–54]. The most pronounced bone deficit was seen in
VLBW adults [51,53]. Therefore, the reduced BMC in our preterm infants throughout
the first years of life is of concern, especially in the LTEA group. The data suggest that
promotion of adequate nutrition with sufficient minerals and vitamin D, and an increase in
weight-bearing exercise, are thus important for former VLBW infants at all ages [53] and
support the hypothesis that improved bone mineralization before discharge may improve
lifelong bone health. In-hospital bone mineral accretion largely depends on enteral intake.
In the present cohort, vitamin D (400 IU/d) was given in addition to standard European
human milk supplements or preterm formula, and Ca, P, and vitamin D were managed
on an individual basis. If 25OH-vitamin D was less than 30 ng/mL at 3 weeks of age,
vitamin D supplementation was increased to 800 IU/d. If serum P was less than 5 mg/dL,
infants received in addition mono-sodium-phosphate (20 mg/kg/d) and Ca-gluconate
(40 mg/kg/d) given in different feedings. Therefore, current Ca and P recommendations
may be insufficient to meet the needs [6,7]. We hypothesize that higher fortifier/formula
mineral content or individual supplementation adjusted to urinary mineral excretion may
be required [55,56].
4.4. Metabolic Outcome
Epidemiologic studies have described metabolic health consequences of preterm birth
such as an increased risk of hypertension and insulin resistance in adult life. However,
growth between birth and expected term and 12–18 months post-term has not been found
to significantly effect later blood pressure or metabolic syndrome [57]. In addition, slower
growth in hospital did not increase the risk of insulin resistance in the present study in
preterm infants. Fasting insulin concentration and the HOMA-IR index are widely accepted
measures of insulin resistance and are closely correlated with more precise but laborious
measures such as an intravenous glucose-tolerance test or the euglycemic-hyperinsulinemic
clamp. No differences (Table 6) were found in HOMA and fasting insulin between the
three groups from 6 to 36 months of age reconfirming previous observations in preterm
infants [40,58]. In addition, preterm birth and slower growth in hospital did not adversely
affect hypothalamic–pituitary–adrenal axis activation. Basal morning cortisol levels were
not increased in preterm infants and were lowest in preterm infants with slower in hospital
growth. Long-term follow up is required to analyze whether differences in hypothalamic–
pituitary–adrenal axis activation may develop later in childhood or later on [59].
It has been suggested in VLBW infants that the adverse NICU environment (especially
inappropriate nutrition and increased physiological stress) during the critical early weeks
ex utero leads to programmed changes in growth and in the GH-IGF-IGF binding protein
axis [60]. In previous studies in VLBW infants, regardless of whether they were AGA
or SGA, low plasma IGF-1 and IGFBP-3 levels were found in mid-childhood, suggesting
partial GH resistance [60]. In contrast to these previous observations, in the present study,
there was virtually no difference between the three groups with regard to IGFBP-1 and
IGFBP-3. However, there was a significant group effect with regard to IGF-1. IGF-1 values
were higher in preterm infants than in term infants at all points of time. These data suggest
that the improved nutritional intake of preterm infants in hospital may have prevented
the development of partial GH resistance. Long term follow-up and further analysis of the
GH-IGF-IGF binding protein axis is required.
There was no significant difference between the groups with regard to leptin, sOB-R,
leptin/sOB-R, adiponectin, ghrelin, and acylated ghrelin. At 6 months of age leptin/sOB-R
ratio only was significantly lower in LTEA preterm infants compared to term infants. At
this point of time the difference in FM% between LTEA and term infants was at a maximum.
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However, there was a significant difference between the groups in resistin levels. Resistin
was consistently higher in LTEA infants at all times (Table 6, exception at 36 weeks). In a
cross-sectional case control study of prepubertal children who were former VLBW infants
with extrauterine growth retardation (appropriate for gestation at birth and less than p3 at
36 weeks), increased resistin and reduced adiponectin levels were observed [61]. Therefore,
early programming of adipose tissue macrophage activation increasing the risk for later
metabolic disease cannot be excluded. Further follow up of the infants is required.
4.5. Neurodevelopmental Outcome
Finally, our study adds to the sad growing body of evidence indicating that extremely
preterm birth with very low birth weight impairs neurodevelopmental outcome. Growth
is associated with neurodevelopment in VLBW preterm infants [57]. The LTEA infants
presented lower head circumference in contrast to term infants. Within our target energy
and protein intakes, neither energy nor protein intake but gestational age, birth weight,
and illness severity were major determinants of in-hospital growth [8]. Therefore, we
hypothesize that higher in-hospital target energy and protein intakes may improve in
hospital growth and the neurodevelopmental outcome [62]. However, this hypothesis
remains to be proven, and the safety with regard to body composition and metabolic
programming needs to be evaluated as well.
4.6. Strengths and Limitations
The major strengths of the present study are the meticulous longitudinal assessment
of children’s growth during infancy and the use of DXA to measure total and regional body
composition. Thyroid dysfunction is increased in preterm infants and has been shown to
impact outcome [63]. In our infants the assessment of the thyroid status was part of the
clinical routine. In the present study thyroid function was investigated at the beginning of
the study in every patient. It was found to be normal, and further systematic assessment of
thyroid function was stopped. As in any observational study, the most important limitation
is that we cannot infer causality based on the data.
5. Conclusions
Our results demonstrate that from six months of corrected age, and into the third year
of life, gain in weight, length and head circumference, mid arm circumference, adiposity,
FFM mass, and bone mineralization in preterm infants are less than in term infants and
influenced by nutritional status at discharge. In hospital VLBW infants may require a
higher nutrient intake. Postnatal body composition patterns indicate FFM proportional
to height but lower FMI in LTEA preterm infants than term infants, with no evidence of
increased truncal fat in preterm infants. Furthermore, preterm infants had poorer motor
and cognitive outcomes than term infants. Longer-term consequences of this growth and
body composition pattern should be studied. Since growth restriction may have permanent
adverse effects, a higher in-hospital target nutrient intake is required to improve growth in
these preterm infants. The clinical significance of the present lower adiposity findings is
unclear. We hypothesize that this could result in a reduction in the risk of obesity. Thus,
especially LTEA VLBW preterm infants would appear to benefit from targeted preventive
interventions to improve growth, bone mineralization, and neurodevelopmental outcome
without increasing the obesity risk. Further follow-up of our infants is required.
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